Page last updated: 2024-10-22

amlexanox and Fatty Liver

amlexanox has been researched along with Fatty Liver in 2 studies

amlexanox: SRA-A antagonist;structure given in first source
amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.

Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Reilly, SM1
Chiang, SH1
Decker, SJ1
Chang, L1
Uhm, M1
Larsen, MJ1
Rubin, JR1
Mowers, J1
White, NM1
Hochberg, I1
Downes, M1
Yu, RT1
Liddle, C1
Evans, RM1
Oh, D1
Li, P1
Olefsky, JM1
Saltiel, AR1
Cruz, VH1
Arner, EN1
Wynne, KW1
Scherer, PE1
Brekken, RA1

Other Studies

2 other studies available for amlexanox and Fatty Liver

ArticleYear
An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.
    Nature medicine, 2013, Volume: 19, Issue:3

    Topics: Aminopyridines; Animals; Anti-Allergic Agents; Anti-Obesity Agents; Cell Line; Diet, High-Fat; Energ

2013
Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction.
    Molecular metabolism, 2018, Volume: 16

    Topics: Aminopyridines; Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Fatty Liver; I-kappa B

2018